Literature DB >> 2327697

Human leukocyte antigens -A, -B, -C, and -DR and nasopharyngeal carcinoma in northern China.

X N Zhu1, R Chen, F H Kong, W Liu.   

Abstract

We observed HLA associations in patients with nasopharyngeal carcinoma from northern China. There was an increased risk of nasopharyngeal carcinoma associated with HLA-B35 and a difference in the HLA association between patients with early- and late-onset disease. The frequency of B35 was significantly higher in patients than in control subjects, especially in early-onset patients (less than 30 years old). Late-onset patients had a higher frequency of DR2 as compared with normal subjects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327697     DOI: 10.1177/000348949009900407

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  5 in total

1.  Pathobiology of selected tumors of the base of the skull.

Authors:  L Barnes
Journal:  Skull Base Surg       Date:  1991

Review 2.  The biology and pathology of selected skull base tumors.

Authors:  L Barnes; S B Kapadia
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  HLA association with nasopharyngeal carcinoma in southern Tunisia.

Authors:  Hafedh Makni; Jamel Daoud; Hanène Ben Salah; Nedia Mahfoudh; Olfa Haddar; Héla Karray; Tahya Boudawara; Abdelmonême Ghorbel; Abdelmajid Khabir; Mounir Frikha
Journal:  Mol Biol Rep       Date:  2009-08-28       Impact factor: 2.316

4.  Gender-specific associations between MICA-STR and nasopharyngeal carcinoma in a southern Chinese Han population.

Authors:  Wei Tian; Xiao-Min Zeng; Li-Xin Li; He-Kun Jin; Qi-Zhi Luo; Fan Wang; Shi-Shi Guo; Ya Cao
Journal:  Immunogenetics       Date:  2006-03-18       Impact factor: 2.846

5.  Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study.

Authors:  N Kongruttanachok; S Sukdikul; S Setavarin; V Kerekhjanarong; P Supiyaphun; N Voravud; Y Poovorawan; A Mutirangura
Journal:  BMC Cancer       Date:  2001-05-25       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.